All In Biotech

Drug Trial Radar · NCT02616562

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

A Randomised, Multinational, Active-controlled, (Open-labelled), Dose Finding, (Double-blinded), Parallel Group Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

76

Actual

Start

Mar 31, 2016

Primary completion

Sep 26, 2024

Study completion Sep 26, 2024

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment naïve pre-pubertal children with growth hormone deficiency. The main trial period will consist of 26 weeks of treatment, followed by a 26 week extension period.

Conditions

  • Growth Hormone Disorder
  • Growth Hormone Deficiency in Children

Interventions

  • somapacitanDrug

    Administered subcutaneously (s.c., under the skin) once-weekly.

  • Norditropin® FlexPro® penDrug

    Administered subcutaneously (s.c., under the skin) once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Height Velocity (HV) (cm/Year) During the First 26 Weeks of Treatment, Measured as Standing Height With StadiometerTime frame: Baseline (week 0), week 26
  2. Cohort II and Cohort III - Adverse Events Rate, Including Injection Site Reactions in Children With GHD.Time frame: From week 156 up to week 364

Locations

89 sites in 14 countries. Site status is shown where the registry gives one.

  • Children's of Alabama

    Birmingham, Alabama

  • Children's Hospital Los Angeles - Endocrinology

    Los Angeles, California

  • Mattel Children's Hospital at UCLA

    Los Angeles, California

  • Valley Children's Hospital

    Madera, California

  • Novo Nordisk Clinical Trial Call Center

    San Diego, California

  • The Regents of the Univ of CA

    San Diego, California

  • Rocky Mt Ped and Endo

    Centennial, Colorado

  • Ped Endo Assoc PC-G.V

    Greenwood Village, Colorado

  • Nemours/AI duPont Hosp-Chld

    Wilmington, Delaware

  • The Endocrine Center

    Pembroke Pines, Florida

  • Childrens Hospital of Chicago

    Chicago, Illinois

  • Riley Hospital For Children

    Indianapolis, Indiana

  • Novo Nordisk Clinical Trial Call Center

    Minneapolis, Minnesota

  • University of Minnesota_Minneapolis_2

    Minneapolis, Minnesota

  • Goryeb Children's Hospital

    Morristown, New Jersey

  • Novo Nordisk Clinical Trial Call Center

    Morristown, New Jersey

  • Rutgers-Rwjms

    New Brunswick, New Jersey

  • UBMD Peds-Div of Endo/Diabetes

    Buffalo, New York

  • Novo Nordisk Clinical Trial Call Center

    Mineola, New York

  • NYU Langone Hospital-LI

    Mineola, New York

  • CCHMC_Cinc

    Cincinnati, Ohio

  • Novo Nordisk Clinical Trial Call Center

    Cincinnati, Ohio

  • University Of Oklahoma-Tulsa

    Tulsa, Oklahoma

  • Dell Pediatric Research Institute

    Austin, Texas

  • Endocrine Associates Of Dallas

    Plano, Texas

  • Children's Hsptl Of The Kings

    Norfolk, Virginia

  • MultiCare Inst for Res & Innov

    Tacoma, Washington

  • Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie

    Graz, Austria

  • Site not named

    Graz, Austria

  • LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde

    Salzburg, Austria

  • LKH St. Poelten, Kinder-und Jugendheilkunde

    Sankt Pölten, Austria

  • Landeskrankenhaus Villach

    Villach, Austria

  • Salzkammergut-Klinikum Vöcklabruck

    Vöcklabruck, Austria

  • Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)

    Linz, Upper Austria, Austria

  • UZ Brussel

    Brussels, Belgium

  • Site not named

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc - Serv. Pédiatrie

    Brussels, Belgium

  • UZ Leuven - Kindergeneeskunde

    Leuven, Belgium

  • CHU de Liège, site N.-D. des Bruyères

    Liège, Belgium

  • Serviço de Endocrinologia e Metabologia do HC-UFPR

    Curitiba, Paraná, Brazil

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.